Statera Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011 - 2006
Cost of Revenue	0.49	0	0	0	0	0	0	0	0	0	Upgrade
Gross Profit	-0.49	0	0	0	0	0	0	0	0	0	Upgrade
Selling, General & Admin	18.49	5.24	2.23	2.32	2.5	3.38	6.36	8,470	12,039	11,116	Upgrade
Research & Development	11.83	5.26	0.59	3.62	5.05	6.5	7.14	9,654	19,526	22,502	Upgrade
Other Operating Expenses	-1.49	-0.46	-0.29	0	0	0	0	0	0	0	Upgrade
Operating Expenses	28.83	10.5	2.81	5.94	7.55	9.87	13.5	18,124	31,565	33,617	Upgrade
Operating Income	38.68	-10.5	-2.81	-4.8	-5.6	-6.36	-10.79	-14,421.94	-23,076.76	-30,046.61	Upgrade
Interest Expense	-4.56	1.13	0.12	0	0	0.26	-0.1	-1,089.58	83.13	-70.02	Upgrade
Other Expense / Income	145.11	0.46	0.29	-1.19	4.11	-3.96	1.95	-14,961.46	-5,897.01	-11,742.45	Upgrade
Pretax Income	-101.88	-12.09	-3.22	-3.61	-9.71	-2.66	-12.64	1,629	-17,262.88	-18,234.14	Upgrade
Income Tax	72.53	1.13	0.12	0	0	0	0	0	0	0	Upgrade
Net Income	-174.41	-13.22	-3.35	-3.61	-9.71	-2.66	-12.64	1,629	-17,262.88	-18,234.14	Upgrade
Shares Outstanding (Basic)	35	26	26	11	11	11	7	2,703	45,003	37,389	Upgrade
Shares Outstanding (Diluted)	35	26	26	11	11	11	7	2,703	45,003	37,389	Upgrade
Shares Change	36.88%	-	127.11%	0.91%	1.87%	55.62%	-99.74%	-93.99%	20.36%	14.82%	Upgrade
EPS (Basic)	-4.97	-0.52	-0.13	-0.32	-0.87	-0.24	-1.79	0.60	-0.38	-0.49	Upgrade
EPS (Diluted)	-4.97	-0.52	-0.13	-0.32	-0.87	-0.24	-1.79	0.60	-0.38	-0.49	Upgrade
Free Cash Flow	-28.38	-5.09	-0.24	-4.61	-6.61	-5.04	-12.08	-14,455.19	-23,102.65	-20,649.5	Upgrade
Free Cash Flow Per Share	-0.81	-0.20	-0.01	-0.41	-0.59	-0.46	-1.71	-5.35	-0.51	-0.55	Upgrade
EBITDA	38.93	-10.5	-2.81	-4.8	-5.6	-6.36	-10.79	-14,421.94	-23,076.76	-30,046.61	Upgrade
Depreciation & Amortization	0.26	0	0.01	0.02	0.02	0.06	0.14	200.79	376.21	479.6	Upgrade
EBIT	38.68	-10.5	-2.83	-4.82	-5.62	-6.42	-10.93	-14,622.73	-23,452.97	-30,526.2	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.